Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | -5.31% | -11.57% | -31.81% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.81% | 217M | |
+7.56% | 223B | |
+11.28% | 195B | |
+18.55% | 144B | |
+29.61% | 111B | |
+2.32% | 65.19B | |
+13.77% | 53.02B | |
+2.68% | 50.28B | |
+6.59% | 44.15B | |
+1.73% | 36.45B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating